Please login to the form below

Not currently logged in
Email:
Password:

Argenx

This page shows the latest Argenx news and features for those working in and with pharma, biotech and healthcare.

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

the early stage of the programme and also that Argenx is also retaining co-promotion rights in the US. ... In that market the companies have agreed to share economics 50/50 on a royalty basis, while Argenx will get double-digit sales royalties elsewhere.

Latest news

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... However the argenx deal is an option not a license and has lower royalty rates.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics